


REMARKS

The Specification has been amended to include Sequence ID listings of the nucleotide and amino acid sequences disclosed at Figure 14, and the sequences disclosed at pages 13 and 14 of the Specification. The Sequence ID listing is being filed to conform the application to the requirements set forth in 37 C.F.R. §§ 1.821 to 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted Sequence ID listing in computer readable form is also being submitted herewith. Applicant submits that the paper copy and the computer readable form of the Sequence ID listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. No new matter has been added as a result of this amendment.

Applicants have attached a copy of the Notice concerning compliance with the requirement for disclosure of sequence listings as per the Instructions in the Formalities Letter.

No fees are believed to be due as a result of this Response. If however, any fees are due as a result of the submission of this Sequence Listing, the Assistant Commissioner for Patents is hereby authorized to charge such fees to Deposit Account No. 10-0447 (Reference No. 48279.3).

Respectfully submitted,
JENKENS & GILCHRIST, P.C.



Andre M. Szuwalksi
Reg. No. 35,701

JENKENS & GILCHRIST, P.C.
1445 Ross Avenue, Suite 3200
Dallas, Texas 75202-2799
Telephone: 214-855-4795
Facsimile: 214-855-4300